Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1988-9-26
|
| pubmed:abstractText |
Standard chemotherapy for disseminated germ cell tumors (GCT) cures most patients but causes considerable acute toxicity, including treatment-related death due to septicemia during neutropenia and pulmonary fibrosis. In addition, chronic and delayed toxicities, particularly Raynaud's phenomenon, have been reported in 6% to 37% of treated patients. In an attempt to minimize the acute and chronic effects of treatment which are related primarily to vinblastine and bleomycin, a randomized trial comparing the efficacy and toxicity of vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin (VAB-6) and etoposide + cisplatin (EP) was conducted on 164 eligible patients with good-prognosis GCT. Seventy-nine of 82 (96%) patients receiving VAB-6 and 76/82 (93%) receiving EP achieved a complete remission (CR) with or without adjunctive surgery. Similar proportions of patients in both arms were found at surgery to have necrosis/fibrosis or mature teratoma. With a median follow-up of 24.4 months in the VAB-6 arm and 25.9 months in the EP arm, the total, relapse-free, and event-free survival distributions were similar in the two arms. Patients receiving EP experienced less emesis (P = .05), higher nadir WBC (P = .06) and platelet counts (P = .01), less magnesium wasting (P = .0001), less mucositis (P = .09), and no pulmonary toxicity. No treatment-related mortality was observed. EP is an efficacious and less toxic regimen and is recommended for good-prognosis patients with disseminated GCT.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Dactinomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
1231-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2457657-Adolescent,
pubmed-meshheading:2457657-Adult,
pubmed-meshheading:2457657-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2457657-Bleomycin,
pubmed-meshheading:2457657-Cisplatin,
pubmed-meshheading:2457657-Clinical Trials as Topic,
pubmed-meshheading:2457657-Cyclophosphamide,
pubmed-meshheading:2457657-Dactinomycin,
pubmed-meshheading:2457657-Dysgerminoma,
pubmed-meshheading:2457657-Etoposide,
pubmed-meshheading:2457657-Female,
pubmed-meshheading:2457657-Humans,
pubmed-meshheading:2457657-Male,
pubmed-meshheading:2457657-Middle Aged,
pubmed-meshheading:2457657-Neoplasms, Germ Cell and Embryonal,
pubmed-meshheading:2457657-Prognosis,
pubmed-meshheading:2457657-Random Allocation,
pubmed-meshheading:2457657-Testicular Neoplasms,
pubmed-meshheading:2457657-Vinblastine
|
| pubmed:year |
1988
|
| pubmed:articleTitle |
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
|
| pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|